LG Chem announced Thursday its entry into the Canadian aesthetic filler market with the launch of its hyaluronic acid filler YVOIRE (Classic Plus, Volume Plus).

The company hosted a launch event in Toronto on Nov. 28, attended by more than 500 cosmetic specialists and stakeholders.

YVOIRE is the first Korean-made filler to receive Canadian medical device approval, granted in January.

LG Chem leveraged clinical trial data from Canada and other regions, including Europe, to secure approval. The company views Canada as a strategic market for expanding its presence in the Americas.

LG Chem currently exports YVOIRE to seven countries in the Americas, including Brazil, Mexico, and Argentina. The company plans to build its market share in Canada through targeted commercialization efforts.

According to U.S. market research firm Grand View Research, the Canadian aesthetic filler market is expected to grow from 400 billion won ($279 million) in 2023 to 700 billion won by 2030. LG Chem aims to secure a double-digit market share by introducing its premium filler line, Y-Solution, in addition to YVOIRE.

"We have proactively invested in clinical development in Europe and China to expand YVOIRE's global reach," said Jennifer Roh, head of LG Chem’s Aesthetic Business Unit. She added that the company plans to leverage the growing North American demand for Korean medical aesthetic products.